News >

Immune Correlates May Indicate Responsiveness to Ipilimumab in mCRPC

Caroline Seymour
Published: Friday, Apr 03, 2020

Sumit Subudhi, MD, PhD, assistant professor of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center

Sumit Subudhi, MD, PhD

A subset of patients with metastatic castration-resistant prostate cancer (mCRPC) who have low tumor mutational burden (TMB) may benefit from checkpoint inhibition with ipilimumab (Yervoy) if the tumor has a high density of CD8-positive T cells and increased interferon (IFN)-gamma signaling, according to findings from a phase II study published in Science Translational Medicine.1

“Our findings indicate that anti–CTLA-4 immune checkpoint therapy warrants additional studies in order to develop treatment strategies that may improve survival of patients with metastatic prostate cancer,” Sharma concluded.


  1. Subudhi SK, Vence L, Zhao H, et al. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 2020;12(537). doi: 1126/scitranslmed.aaz3577
  2. Immunotherapy effective in metastatic prostate cancers with specific markers of immune activation [news release]. The University of Texas MD Anderson Cancer Center. Published April 1, 2020. Accessed April 2, 2020.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication